Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
Colorcon
Baxter
Farmers Insurance
Covington
Federal Trade Commission
US Army
Johnson and Johnson

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020624

« Back to Dashboard

NDA 020624 describes ANZEMET, which is a drug marketed by Us Pharm Holdings and is included in two NDAs. It is available from two suppliers. Additional details are available on the ANZEMET profile page.

The generic ingredient in ANZEMET is dolasetron mesylate. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dolasetron mesylate profile page.
Summary for 020624
Tradename:ANZEMET
Applicant:Us Pharm Holdings
Ingredient:dolasetron mesylate
Patents:0
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength100MG/5ML (20MG/ML)
Approval Date:Sep 11, 1997TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength12.5MG/0.625ML (20MG/ML)
Approval Date:Sep 11, 1997TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength500MG/25ML (20MG/ML)
Approval Date:Dec 11, 2001TE:RLD:No

Expired US Patents for NDA 020624

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Daiichi Sankyo
Accenture
Chubb
Argus Health
Baxter
McKinsey
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.